Dentsply Sirona Reports Third Quarter 2026 Results
DENTSPLY SIRONA Inc. (XRAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Dentsply Sirona Reports Third Quarter 2026 Results News Summary • Q3 2026 net sales of $836 million • Q3 2026 GAAP gross margin of 52.9%, GAAP diluted loss per share of ($0.01) • Q3 2026 adjusted gross margin of 54.5%, adjusted EBITDA margin of 17.3%, adjusted EPS of $0.29 • Achi
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The earnings release introduces new financial metrics and a modest FY guidance, offering traders fresh data for positioning.
Market read
The report provides primary earnings data for a mid‑cap healthcare stock, directly influencing short‑term price action.
What to watch
The $39M inventory adjustment and share repurchase program may provide hidden support.
Dentsply Sirona Reports Third Quarter 2026 Results
Net sales declined 7.6% as reported, adjusted EBITDA declined 13.3%, and adjusted EPS declined 29.4%, while GAAP gross margin expanded to 52.9% and Wellspect Healthcare delivered record quarterly sales with 10.1% as-reported growth.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 net salesGAAP | $836M | – | (7.6%) |
| Q3 2026 constant currency salesnon-GAAP | (7.0%) | – | (7.0%) |
| Q3 2026 cost of products soldGAAP | $393M | – | – |
| Q3 2026 gross profitGAAP | $443M | – | 0.3% |
| Q3 2026 gross marginGAAP | 52.9% | – | – |
| Q3 2026 adjusted gross profitnon-GAAP | $456M | – | – |
| Q3 2026 adjusted gross marginnon-GAAP | 54.5% | – | – |
| Q3 2026 selling, general, and administrative expensesGAAP | $363M | – | – |
| Q3 2026 research and development expensesGAAP | $42M | – | – |
| Q3 2026 goodwill and intangible asset impairmentsGAAP | $3M | – | – |
| Q3 2026 restructuring and other (income) expensesGAAP | ($2) million | – | – |
| Q3 2026 operating income (loss)GAAP | $37M | – | – |
| Q3 2026 adjusted operating incomenon-GAAP | $95M | – | – |
| Q3 2026 adjusted operating marginnon-GAAP | 11.5% | – | – |
| Q3 2026 interest expense, netGAAP | $25M | – | – |
| Q3 2026 other income, netGAAP | ($14) million | – | – |
| Q3 2026 income (loss) before income taxesGAAP | $26M | – | – |
| Q3 2026 provision for income taxesGAAP | $29M | – | – |
| Q3 2026 net (loss) incomeGAAP | ($3) million | – | – |
| Q3 2026 net (loss) income attributable to Dentsply SironaGAAP | ($2) million | – | – |
| Q3 2026 diluted loss per shareGAAP | ($0.01) | – | NM |
| Q3 2026 adjusted EBITDAnon-GAAP | $146M | – | (13.3%) |
| Q3 2026 adjusted EBITDA marginnon-GAAP | 17.3% | – | – |
| Q3 2026 adjusted net income attributable to Dentsply Sironanon-GAAP | $59M | – | – |
| Q3 2026 adjusted EPSnon-GAAP | $0.29 | – | (29.4%) |
| Q3 2026 net cash provided by operating activitiesGAAP | $32M | – | – |
| Q3 2026 capital expendituresGAAP | ($32) million | – | – |
| Q3 2026 free cash flownon-GAAP | $0 million | – | – |
| Nine months ended September 30, 2026 net salesGAAP | $2.61B | – | – |
| Nine months ended September 30, 2026 gross profitGAAP | $1.36B | – | – |
| Nine months ended September 30, 2026 operating income (loss)GAAP | $84M | – | – |
| Nine months ended September 30, 2026 net (loss) income attributable to Dentsply SironaGAAP | $25M | – | – |
| Nine months ended September 30, 2026 diluted earnings per common share attributable to Dentsply SironaGAAP | $0.12 | – | – |
| Nine months ended September 30, 2026 net cash provided by operating activitiesGAAP | $171M | – | – |
| Nine months ended September 30, 2026 capital expendituresGAAP | ($128) million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Connected Technology SolutionsNo segment-specific driver was provided. | $230M | – | (11.0)% as reported; (10.1)% constant currency |
| Essential Dental SolutionsNo segment-specific driver was provided. | $343M | – | (4.0)% as reported; (3.6)% constant currency |
| Orthodontic and Implant SolutionsThe Company cited progress in priority areas of implants and endodontics. | $171M | – | (16.6)% as reported; (16.2)% constant currency |
| Wellspect HealthcareAchieved record quarterly sales; completed the U.S. Surity TM portfolio with the launch of the Surity TM Urinary Management System. | $92M | – | 10.1% as reported; 11.0% constant currency |
FY2026 outlook
- Revenueapproximately $3.5 billion in net sales
- Noteadjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds
Capital returns
- In the third quarter of 2026, the Company repurchased 1.2 million shares of its common stock for a total of approximately $13 million.
- $25 million returned to stockholders through share repurchases in the first nine months of 2026.
- Cash dividends paid were ($32) million for the nine months ended September 30, 2026, compared to ($96) million for the nine months ended September 30, 2025.
What drove it
- Gross profit and adjusted EBITDA included a $39 million benefit from refinement of the estimate to eliminate unrealized profit in inventory.
- The estimate refinement reduced reported net loss and increased adjusted net income by approximately $30 million. The Company said it represents a cumulative impact and equivalent impacts are not expected in future.
- Wellspect Healthcare reported record quarterly sales and 10.1% as-reported growth.
- Management cited progress in implants and endodontics, expanded U.S. dealer network access, and investments in sales force, clinical education and innovation.
- The Company completed the U.S. Surity TM portfolio with the launch of the Surity TM Urinary Management System.
Concerns
- Total net sales declined 7.6% as reported and 7.0% in constant currency.
- Connected Technology Solutions, Essential Dental Solutions, and Orthodontic and Implant Solutions each reported lower sales.
- Adjusted EBITDA declined 13.3%, adjusted EBITDA margin was 17.3% versus 18.4%, and adjusted EPS declined 29.4%.
- Third-quarter operating cash flow was $32 million versus $79 million, primarily driven by unfavorable working capital.
- Third-quarter free cash flow was $0 million versus $40 million.
- The $39 million inventory-estimate benefit is cumulative, and the Company does not expect equivalent impacts in future.
What to watch
- Execution of the Return-to-Growth Action Plan amid challenging industry-wide conditions.
- Sales trends in Connected Technology Solutions, Essential Dental Solutions, and Orthodontic and Implant Solutions.
- Whether record Wellspect Healthcare sales and the U.S. Surity TM portfolio launch support continued growth.
- Working-capital effects on operating cash flow and free cash flow.
- Delivery against FY2026 outlook of approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds.
Balance sheet and cash flow
- Cash and cash equivalents were $195 million as of September 30, 2026, compared to $326 million as of December 31, 2025.
- Notes payable and current portion of long-term debt were $215 million as of September 30, 2026, compared to $313 million as of December 31, 2025.
- Long-term debt was $1,985 million as of September 30, 2026, compared to $2,015 million as of December 31, 2025.
- Inventories, net were $707 million as of September 30, 2026, compared to $642 million as of December 31, 2025.
- Accounts and notes receivable-trade, net were $605 million as of September 30, 2026, compared to $688 million as of December 31, 2025.
- Total assets were $5,190 million as of September 30, 2026, compared to $5,429 million as of December 31, 2025.
- Total liabilities were $3,836 million as of September 30, 2026, compared to $4,089 million as of December 31, 2025.
- Total equity was $1,354 million as of September 30, 2026, compared to $1,340 million as of December 31, 2025.
- Nine-month net cash used in investing activities was ($135) million, compared to ($87) million in the prior-year period.
- Nine-month net cash used in financing activities was ($158) million, compared to net cash provided by financing activities of $19 million in the prior-year period.
- Cash and cash equivalents at end of period were $195 million for the nine months ended September 30, 2026, compared to $363 million for the prior-year period.
Analysis
Dentsply Sirona reported Q3 2026 net sales of $836 million, down 7.6% as reported and down 7.0% in constant currency. The sales decline was broad across Connected Technology Solutions, Essential Dental Solutions, and Orthodontic and Implant Solutions. Wellspect Healthcare was the exception, generating record quarterly sales of $92 million and 10.1% as-reported growth.
Profitability improved sharply on a reported GAAP comparison affected by prior-year impairment charges. GAAP gross profit was $443 million versus $441 million, and GAAP gross margin was 52.9% versus 48.8%. However, adjusted gross profit was $456 million versus $475 million, adjusted EBITDA was $146 million versus $167 million, and adjusted EBITDA margin was 17.3% versus 18.4%. The quarter included a $39 million benefit from refinement of an inventory estimate, which the Company said reduced reported net loss and increased adjusted net income by approximately $30 million; equivalent impacts are not expected in future.
GAAP net loss attributable to Dentsply Sirona narrowed to ($2) million from ($427) million, while adjusted net income attributable to Dentsply Sirona was $59 million versus $84 million. GAAP diluted loss per share was ($0.01), and adjusted EPS was $0.29 versus $0.42. The reported year-over-year GAAP improvement also reflected goodwill and intangible asset impairments of $3 million in Q3 2026 versus $262 million in Q3 2025.
Cash conversion weakened in the quarter. Operating cash flow was $32 million compared to $79 million, primarily driven by unfavorable working capital, while free cash flow was $0 million compared to $40 million. Cash and cash equivalents were $195 million at September 30, 2026, long-term debt was $1,985 million, and the Company repurchased 1.2 million shares for approximately $13 million during the quarter.
The Company updated FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30, excluding the $0.17 one-time benefit from tariff refunds. Management emphasized execution of its Return-to-Growth Action Plan, including sales force, clinical education and innovation investments. The key reported tension is between that execution agenda and the current broad-based sales decline outside Wellspect Healthcare, alongside lower adjusted earnings and weaker quarterly free cash flow.
Management, verbatim
We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions.
Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona
We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network.
Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona
Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth.
Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona
Not in the filing
stated, not guessed- Previous-release outlook was not provided; comparison of actual results with prior guidance is unavailable.
- Prior-quarter figures and sequential comparisons were not provided for the reported operating metrics.
- FY2026 guidance for gross margin, operating expenses, tax rate, GAAP EPS, operating cash flow, free cash flow, capital expenditures, dividends, and share repurchases was not provided.
- A quantitative reconciliation of expected GAAP earnings per diluted share to expected adjusted earnings per diluted share was not provided because the Company stated it could not predict certain items with reasonable certainty.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Dentsply Sirona filed a Form 8‑K reporting its Q3 2026 results and revising its full‑year outlook.
Ticker impact
Q3 2026 net sales of $836M and updated FY2026 outlook to approximately $3.5B in net sales and adjusted EPS $1.20‑$1.30.
potential downside as the market prices in the modest outlook
The earnings release provides fresh numbers and a revised FY outlook, which traders will digest immediately.
Market effects
Dental equipment sector may see modest re‑rating based on Dentsply Sirona's performance.
North American market could see slight pressure on related healthcare stocks.
Limited to investors tracking US dental‑technology equities.
Counterpoint
If the updated outlook is viewed as a floor rather than a ceiling, the stock could rally on a perceived upside.
Key entities
- CompanyDentsply Sirona Inc.
World's largest diversified manufacturer of professional dental products.





